Updates from the Phase II trials of glofitamab and epcoritamab for R/R LBCL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2024-12-16
Просмотров: 211
Описание:
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses updates from the pivotal Phase II studies of glofitamab and epcoritamab in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who have had two or more prior lines of treatment. Dr Hutchings comments on durable response rates, suggesting a curative potential for both drugs. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
